Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.46 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.46 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.46 |
| ▸ | EPOR | P19235 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.36 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7785339 | 0.97 | TPSAB1 (0.47) | TPSAB1TPSD1TPSG1EPORL3MBTL1 | |
| SCHEMBL5712142 | 0.93 | TPSAB1 (0.52) | TPSAB1TPSD1TPSG1EPORL3MBTL1 | |
| SCHEMBL28480221 | 0.93 | TPSAB1 (0.52) | TPSAB1TPSD1TPSG1EPORL3MBTL1 | |
| SCHEMBL1021829 | 0.93 | TPSAB1 (0.52) | TPSAB1TPSD1TPSG1EPORL3MBTL1 | |
| SCHEMBL5692891 | 0.90 | EPOR (0.55) | TPSAB1TPSD1TPSG1EPORL3MBTL1 | |
| SCHEMBL375887 | 0.90 | TPSAB1 (0.53) | TPSAB1TPSD1TPSG1EPORL3MBTL1 | |
| SCHEMBL4150947 | 0.90 | TPSAB1 (0.53) | TPSAB1TPSD1TPSG1EPORL3MBTL1 | |
| SCHEMBL3820596 | 0.90 | TPSAB1 (0.53) | TPSAB1TPSD1TPSG1EPORL3MBTL1 | |
| SCHEMBL28477064 | 0.87 | TPSAB1 (0.46) | TPSAB1TPSD1TPSG1EPORSYK | |
| SCHEMBL28477062 | 0.87 | TPSAB1 (0.46) | TPSAB1TPSD1TPSG1EPORSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010034342-A1 | Substituted urea and isothiourea derivatives as no synthase inhibitors | OPLINGER JEFFREY ALAN (US) | 2001-10-25 | — | — | US | disclosed |
| US-6225305-B1 | Substituted urea and isothiorea derivatives as no synthase inhibitors | GLAXO WELLCOME INC. | 2001-05-01 | — | — | US | disclosed |
| EP-0723438-A1 | SUBSTITUTED UREA AND ISOTHIOUREA DERIVATIVES AS NO SYNTHASE INHIBITORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-07-31 | — | — | EP | disclosed |
| WO-1995009619-A2 | SUBSTITUTED UREA AND ISOTHIOUREA DERIVATIVES AS NO SYNTHASE INHIBITORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034342-A1 | Substituted urea and isothiourea derivatives as no synthase inhibitors | NOS1, NOS2, SLC14A1 | TPSAB1 3387/4885TPSD1 3172/4885TPSG1 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.